Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Amoxicillin
Drug ID BADD_D00129
Description Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972.[A190648] Amoxicillin has similar activity to [penicillin] and [ampicillin], but leads to higher serum concentrations than ampicillin.[A190648] Amoxicillin was granted FDA approval on 18 January 1974.[L11644]
Indications and Usage Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract.[L11656,L11659] Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections.[L11650,L7880,L11653] Amoxicillin is given with omeprazole in the treatment of _H. pylori_.[L9743,L11647]
Marketing Status approved; vet_approved
ATC Code J01CA04
DrugBank ID DB01060
KEGG ID D00229; D07452
MeSH ID D000658
PubChem ID 33613
TTD Drug ID D0F6EO
NDC Product Code 0781-5060; 55657-101; 55657-106; 59651-099; 65862-274; 0093-2268; 0093-4161; 43063-563; 0143-9886; 50090-0304; 50090-0858; 50090-1511; 50090-5863; 50090-5880; 51655-156; 53002-0130; 53002-2080; 55289-182; 57237-029; 61919-672; 61919-716; 63187-200; 63187-591; 68071-1760; 68071-2908; 68071-4548; 68788-8240; 70518-0895; 72789-224; 76420-192; 81964-225; 43063-820; 50090-0713; 50090-6056; 50090-6466; 53002-1369; 55289-019; 57237-028; 61919-401; 63187-044; 63187-295; 65862-071; 65862-706; 67296-1156; 68071-4455; 68788-7318; 68788-9948; 70518-2188; 70518-2190; 70518-3294; 71205-177; 71205-436; 76420-112; 76420-508; 0781-6039; 0093-4160; 0143-9285; 43063-341; 63187-262; 63629-7587; 63629-7798; 63629-7801; 68071-2766; 68071-2875; 68071-3119; 68788-6374; 68999-825; 55289-020; 63187-043; 63187-186; 63629-7633; 66267-994; 67296-1894; 68071-4693; 68071-4741; 68788-8324; 71205-035; 71205-422; 0781-6041; 16714-299; 0093-2267; 42571-234; 42708-153; 43063-574; 50090-0288; 50090-1512; 50090-1812; 50090-6351; 53002-2369; 63187-027; 67296-0986; 68071-2558; 68788-8209; 68788-8304; 68788-8325; 68788-9018; 71205-507; 76420-003; 52115-001; 65862-014; 65862-017; 50090-0406; 50090-0407; 50090-6469; 53002-2160; 57237-032; 63187-325; 68071-4953; 70518-2191; 70882-113; 70934-038; 76420-545; 16714-298; 0093-2264; 42708-010; 42708-076; 0143-9888; 0143-9939; 50090-1810; 53002-2090; 63187-029; 63187-399; 63187-880; 65862-707; 68071-2604; 70518-3234; 70882-114; 71205-266; 72789-254; 0781-2613; 0781-5061; 0781-6156; 42708-112; 43063-885; 50090-0301; 50090-0404; 50090-1086; 50090-1347; 61919-135; 63187-013; 63187-335; 63187-343; 63187-729; 65862-015; 65862-016; 65862-070; 68071-2320; 68071-2911; 70518-3228; 76420-573; 80425-0269; 0093-3109; 0093-4155; 50090-1513; 50090-1813; 50090-2251; 50090-6349; 57237-031; 61919-994; 63629-7585; 67296-1126; 68071-1826; 68788-6369; 68788-7323; 68788-8352; 68788-9019; 72189-463; 72789-225; 0781-6157; 81964-205; 83112-031; 0093-2263; 42571-233; 0143-9887; 50090-1826; 50090-6319; 50090-6355; 50436-0031; 53002-2091; 57237-033; 68071-3235; 68788-7414; 68788-9017; 68788-9949; 70934-064; 71205-775; 72189-285; 0781-2020; 76420-138; 82982-022; 0093-3107; 42708-078; 43063-915; 0143-9889; 50090-0302; 50090-0303; 50090-0405; 50090-0709; 50090-1811; 50090-6323; 57237-030; 59115-041
UNII 804826J2HU
Synonyms Amoxicillin | Amoxycillin | Amoxicilline | Amoxicillin Monopotassium Salt | Hydroxyampicillin | Amoxicillin Sodium | Amoxicillin Monosodium Salt | Amoxicillin, (R*)-Isomer | Amoxicillin Anhydrous | Actimoxi | BRL-2333 | BRL 2333 | BRL2333 | Clamoxyl | Penamox | Clamoxyl Parenteral | Clamoxyl G.A. | Polymox | Trimox | Wymox | Amoxicillin Trihydrate | Amoxil
Chemical Information
Molecular Formula C16H19N3O5S
CAS Registry Number 26787-78-0
SMILES CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)C(=O)O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cross sensitivity reaction10.01.01.0360.000153%Not Available
Discharge08.01.03.086--Not Available
Drug-disease interaction08.06.03.0120.000005%Not Available
Dysbiosis12.02.05.053; 07.11.01.0340.000010%Not Available
Electric shock sensation17.02.07.024; 08.06.02.023--Not Available
Encephalopathy neonatal18.04.04.015; 17.13.02.0140.000005%Not Available
Fixed eruption23.03.05.008; 10.01.01.037; 08.01.06.0250.000041%Not Available
Foetal arrhythmia18.03.02.021; 02.03.02.0340.000005%Not Available
Food refusal19.09.03.003; 14.03.01.0140.000005%Not Available
Haemophagocytic lymphohistiocytosis16.32.03.038; 10.02.01.077; 01.05.01.0260.000010%Not Available
Hepatic cytolysis09.01.07.0360.000031%Not Available
Hyperleukocytosis01.02.01.0180.000005%Not Available
Hyperoxaluria20.02.01.0350.000005%Not Available
Immature respiratory system22.11.01.011; 18.04.09.0110.000005%Not Available
Immune thrombocytopenia10.02.01.083; 01.08.01.0130.000005%Not Available
Immune-mediated enterocolitis10.02.01.084; 07.08.01.0210.000007%Not Available
Infusion site discolouration08.02.05.026; 23.03.03.084; 12.07.05.0260.000005%Not Available
Infusion site vesicles23.03.01.036; 12.07.05.038; 08.02.05.0380.000010%Not Available
Intestinal pseudo-obstruction07.02.02.0200.000005%Not Available
Laryngeal dyspnoea02.11.05.007; 22.04.01.0120.000014%Not Available
Laryngeal obstruction22.04.02.0090.000005%
Mucosal disorder08.01.06.0290.000005%Not Available
Neonatal respiratory distress22.11.02.015; 18.04.10.0040.000010%Not Available
Numb chin syndrome17.04.08.006; 16.32.03.0430.000005%Not Available
Periorbital swelling06.08.03.032; 23.04.01.025; 10.01.05.0250.000010%Not Available
Pharyngeal swelling22.04.05.0280.000020%Not Available
Potentiating drug interaction08.06.03.0150.000007%Not Available
Reaction to excipient10.01.01.0420.000012%Not Available
SJS-TEN overlap11.07.01.030; 10.01.01.043; 23.03.01.041; 12.03.01.0690.000014%Not Available
Symmetrical drug-related intertriginous and flexural exanthema23.03.05.012; 10.01.01.0460.000024%Not Available
The 19th Page    First    Pre   19 20    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene